- Home
- GOF vs RARE Comparison
GOF vs RARE Comparison
Compare GOF & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | RARE |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GOF | RARE |
|---|---|---|
| Price | $12.83 | $22.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $73.11 |
| AVG Volume (30 Days) | 789.2K | ★ 4.0M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $630,598,000.00 |
| Revenue This Year | N/A | $19.68 |
| Revenue Next Year | N/A | $19.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $10.96 | $18.41 |
| 52 Week High | $16.76 | $46.50 |
Technical Indicators
Market Signals| Indicator | GOF | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 34.87 |
| Support Level | $12.68 | $22.40 |
| Resistance Level | $13.07 | $24.65 |
| Average True Range (ATR) | 0.18 | 1.53 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 47.46 | 64.17 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.